Your browser doesn't support javascript.
loading
Correction: Synthetic tetracycline-controllable shRNA targeting long non-coding RNA HOXD-AS1 inhibits the progression of bladder cancer.
Li, Jianfa; Zhuang, Chengle; Liu, Yuchen; Chen, Mingwei; Chen, Yincong; Chen, Zhicong; He, Anbang; Lin, Junhao; Zhan, Yonghao; Liu, Li; Xu, Wen; Zhao, Guoping; Guo, Yinglu; Wu, Hanwei; Cai, Zhiming; Huang, Weiren.
Affiliation
  • Li J; Guangdong Province, Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, Clinical Institute of Shantou University Medical College, First Affiliated Hospital of Shenzhen University, Shenzhen, 518039, People's Republic of China.
  • Zhuang C; Guangdong Province, Shantou University Medical College, Shantou, 515041, People's Republic of China.
  • Liu Y; Guangdong Province, Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, Clinical Institute of Shantou University Medical College, First Affiliated Hospital of Shenzhen University, Shenzhen, 518039, People's Republic of China.
  • Chen M; Guangdong Province, Shantou University Medical College, Shantou, 515041, People's Republic of China.
  • Chen Y; Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Institute of Urology, Peking University Shenzhen, Hospital, Shenzhen PKU-HKUST Medical Center, Shenzhen, 518036, People's Republic of China.
  • Chen Z; Guangdong Province, Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, Clinical Institute of Shantou University Medical College, First Affiliated Hospital of Shenzhen University, Shenzhen, 518039, People's Republic of China.
  • He A; Guangdong Province, Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, Clinical Institute of Shantou University Medical College, First Affiliated Hospital of Shenzhen University, Shenzhen, 518039, People's Republic of China.
  • Lin J; Anhui Province People's, Anhui Medical University, Hefei, 230000, Republic of China.
  • Zhan Y; Guangdong Province, Shantou University Medical College, Shantou, 515041, People's Republic of China.
  • Liu L; Guangdong Province, Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, Clinical Institute of Shantou University Medical College, First Affiliated Hospital of Shenzhen University, Shenzhen, 518039, People's Republic of China.
  • Xu W; Guangdong Province, Shantou University Medical College, Shantou, 515041, People's Republic of China.
  • Zhao G; Guangdong Province, Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, Clinical Institute of Shantou University Medical College, First Affiliated Hospital of Shenzhen University, Shenzhen, 518039, People's Republic of China.
  • Guo Y; Anhui Province People's, Anhui Medical University, Hefei, 230000, Republic of China.
  • Wu H; Guangdong Province, Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, Clinical Institute of Shantou University Medical College, First Affiliated Hospital of Shenzhen University, Shenzhen, 518039, People's Republic of China.
  • Cai Z; Guangdong Province, Shantou University Medical College, Shantou, 515041, People's Republic of China.
  • Huang W; Guangdong Province, Key Laboratory of Medical Reprogramming Technology, Shenzhen Second People's Hospital, Clinical Institute of Shantou University Medical College, First Affiliated Hospital of Shenzhen University, Shenzhen, 518039, People's Republic of China.
J Exp Clin Cancer Res ; 42(1): 321, 2023 Nov 28.
Article in En | MEDLINE | ID: mdl-38012784

Full text: 1 Collection: 01-internacional Health context: 1_ASSA2030 / 2_ODS3 Database: MEDLINE Language: En Journal: J Exp Clin Cancer Res Year: 2023 Document type: Article

Full text: 1 Collection: 01-internacional Health context: 1_ASSA2030 / 2_ODS3 Database: MEDLINE Language: En Journal: J Exp Clin Cancer Res Year: 2023 Document type: Article